JP2020517635A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517635A5 JP2020517635A5 JP2019556860A JP2019556860A JP2020517635A5 JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5 JP 2019556860 A JP2019556860 A JP 2019556860A JP 2019556860 A JP2019556860 A JP 2019556860A JP 2020517635 A5 JP2020517635 A5 JP 2020517635A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- cell
- combination
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 241000701161 unidentified adenovirus Species 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 230000027455 binding Effects 0.000 claims 8
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 5
- 230000000174 oncolytic effect Effects 0.000 claims 5
- 244000309459 oncolytic virus Species 0.000 claims 5
- 230000009870 specific binding Effects 0.000 claims 5
- 101710199711 Early E1A protein Proteins 0.000 claims 4
- 241001135569 Human adenovirus 5 Species 0.000 claims 3
- 102000006601 Thymidine Kinase Human genes 0.000 claims 3
- 108020004440 Thymidine kinase Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108050002653 Retinoblastoma protein Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000006837 decompression Effects 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023054969A JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488181P | 2017-04-21 | 2017-04-21 | |
| US62/488,181 | 2017-04-21 | ||
| PCT/US2018/028577 WO2018195427A2 (en) | 2017-04-21 | 2018-04-20 | Oncolytic virotherapy and immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Division JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517635A JP2020517635A (ja) | 2020-06-18 |
| JP2020517635A5 true JP2020517635A5 (enExample) | 2021-05-20 |
| JP7260173B2 JP7260173B2 (ja) | 2023-04-18 |
Family
ID=62196688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556860A Active JP7260173B2 (ja) | 2017-04-21 | 2018-04-20 | 腫瘍溶解性ウイルス療法および免疫療法 |
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023054969A Active JP7620994B2 (ja) | 2017-04-21 | 2023-03-30 | 腫瘍溶解性ウイルス療法および免疫療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11896634B2 (enExample) |
| EP (1) | EP3612202A2 (enExample) |
| JP (2) | JP7260173B2 (enExample) |
| KR (2) | KR20240093758A (enExample) |
| CN (1) | CN110785180B (enExample) |
| AU (2) | AU2018254566B2 (enExample) |
| CA (1) | CA3060573A1 (enExample) |
| NZ (1) | NZ758626A (enExample) |
| SG (1) | SG11201909749PA (enExample) |
| TW (1) | TWI799411B (enExample) |
| WO (1) | WO2018195427A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
| CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CA3060573A1 (en) * | 2017-04-21 | 2018-10-25 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| SG10201801219VA (en) * | 2018-02-13 | 2019-09-27 | Agency Science Tech & Res | Anti-HER2 Antibodies |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2019202118A1 (en) * | 2018-04-20 | 2019-10-24 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
| US11413315B2 (en) * | 2018-04-29 | 2022-08-16 | City Of Hope | Neural stem cell-mediated cancer treatment |
| EP3870297B1 (en) * | 2018-10-25 | 2023-08-30 | Baylor College of Medicine | Oncolytic virotherapy and immunotherapy |
| US11407828B2 (en) | 2019-02-01 | 2022-08-09 | Novarock Biotherapeutics, Ltd. | Anti-CLauDiN 18 antibodies and methods of use thereof |
| CN111743923B (zh) * | 2019-03-27 | 2024-11-08 | 北京康万达医药科技有限公司 | 包含分离的重组溶瘤腺病毒和免疫细胞的治疗剂及其应用 |
| EP3911671A1 (en) * | 2019-04-29 | 2021-11-24 | Mayo Foundation for Medical Education and Research | Multivalent pd-l1 binding compounds for treating cancer |
| EP4054612A4 (en) * | 2019-11-07 | 2023-08-02 | Baylor College of Medicine | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY |
| CN111632146B (zh) * | 2020-05-29 | 2021-09-28 | 中山大学 | Oat抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN111676245B (zh) * | 2020-06-24 | 2022-09-13 | 武汉波睿达生物科技有限公司 | 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用 |
| US20230257706A1 (en) * | 2020-07-07 | 2023-08-17 | Fapon Biotherapy Inc. | T lymphocyte and use thereof |
| CN113425856B (zh) * | 2021-07-07 | 2022-01-04 | 浙江康佰裕生物科技有限公司 | 一种含有基因修饰的溶瘤病毒的药物组合物及其在治疗癌症的用途 |
| US20250121017A1 (en) * | 2021-10-29 | 2025-04-17 | Unm Rainforest Innovations | Oncolytic virotherapy compositions and methods |
| CN114032323B (zh) * | 2021-11-17 | 2023-08-08 | 云南省烟草农业科学研究院 | 一种与雪茄烟抗黑胫病基因紧密连锁的共显性ssr标记及其应用 |
| WO2024042231A1 (en) * | 2022-08-26 | 2024-02-29 | Universite De Namur | Adenovirus-based adjuvants for cancer treatment |
| WO2024229083A1 (en) * | 2023-05-03 | 2024-11-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| CN118930652B (zh) * | 2024-07-29 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT931830E (pt) | 1993-02-16 | 2001-08-30 | Onyx Pharma Inc | Virus citopaticos para terapia e profilaxia de neoplasia |
| US7045347B2 (en) | 1993-06-24 | 2006-05-16 | Advec, Inc. | Helper dependent adenovirus vectors based on integrase family site-specific recombinases |
| US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| US6730507B1 (en) | 1993-06-24 | 2004-05-04 | Merck & Co., Inc. | Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |
| US6080569A (en) | 1993-06-24 | 2000-06-27 | Merck & Co., Inc. | Adenovirus vectors generated from helper viruses and helper-dependent vectors |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| AU4592697A (en) | 1996-09-24 | 1998-04-17 | Dana-Farber Cancer Institute | Method of targeting malignant cells using an e2f responsive promoter |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| US20060275262A1 (en) | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
| KR100523028B1 (ko) | 2003-02-27 | 2005-10-20 | 윤채옥 | 개선된 암세포 특이성과 활성을 가지는 사람 텔로미어역전사효소 프로모터 및 이를 포함하는 재조합 벡터 |
| WO2005086922A2 (en) * | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| ES2612889T3 (es) | 2008-12-22 | 2017-05-19 | Targovax Oy | Vectores adenovíricos oncolíticos y procedimientos y utilizaciones relacionados con los mismos |
| EP2619224A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| EP2619312A1 (en) | 2010-09-24 | 2013-07-31 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| FI123955B (en) | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| PL2623604T3 (pl) | 2012-02-02 | 2015-07-31 | Baylor College Medicine | Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów |
| PL2948553T3 (pl) | 2013-01-25 | 2020-11-16 | Baylor College Of Medicine | Adenowirusowy system dostarczania i ekspresji terapii genowej zależny od pomocnika |
| CA2903582C (en) | 2013-03-14 | 2021-06-08 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CN106831986B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| CN106831987B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
| CA3060573A1 (en) * | 2017-04-21 | 2018-10-25 | Baylor College Of Medicine | Oncolytic virotherapy and immunotherapy |
-
2018
- 2018-04-20 CA CA3060573A patent/CA3060573A1/en active Pending
- 2018-04-20 TW TW107113504A patent/TWI799411B/zh active
- 2018-04-20 SG SG11201909749P patent/SG11201909749PA/en unknown
- 2018-04-20 KR KR1020247016403A patent/KR20240093758A/ko active Pending
- 2018-04-20 KR KR1020197033577A patent/KR102830905B1/ko active Active
- 2018-04-20 WO PCT/US2018/028577 patent/WO2018195427A2/en not_active Ceased
- 2018-04-20 JP JP2019556860A patent/JP7260173B2/ja active Active
- 2018-04-20 US US16/607,066 patent/US11896634B2/en active Active
- 2018-04-20 NZ NZ758626A patent/NZ758626A/en unknown
- 2018-04-20 AU AU2018254566A patent/AU2018254566B2/en active Active
- 2018-04-20 EP EP18725690.4A patent/EP3612202A2/en active Pending
- 2018-04-20 CN CN201880042149.2A patent/CN110785180B/zh active Active
-
2019
- 2019-06-03 US US16/430,347 patent/US10716818B2/en active Active
-
2023
- 2023-03-30 JP JP2023054969A patent/JP7620994B2/ja active Active
-
2025
- 2025-05-09 AU AU2025203355A patent/AU2025203355A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517635A5 (enExample) | ||
| JP2013107899A5 (enExample) | ||
| Belousova et al. | Genetically targeted adenovirus vector directed to CD40-expressing cells | |
| JP2019506841A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2019531728A5 (enExample) | ||
| JP2009544318A5 (enExample) | ||
| JP2015096070A5 (enExample) | ||
| CN102633883A (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2017513502A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| JP2017163973A5 (enExample) | ||
| CN106029889A (zh) | 表达免疫细胞刺激受体激动剂的腺病毒 | |
| JP2016505635A5 (enExample) | ||
| JP2019531093A5 (enExample) | ||
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2010519931A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| JP2015525230A5 (enExample) | ||
| JP2016513471A5 (enExample) | ||
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2019519529A5 (enExample) | ||
| JP2018505893A5 (enExample) | ||
| JP2018531624A5 (enExample) | ||
| WO2009055491A3 (en) | Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres |